133 related articles for article (PubMed ID: 18789222)
21. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
Riester D; Hildmann C; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
[TBL] [Abstract][Full Text] [Related]
23. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
Fang JY
J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
29. [Development of HDAC inhibitors].
Sowa Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929
[TBL] [Abstract][Full Text] [Related]
30. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
31. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.
Garcia-Manero G; Issa JP
Cancer Invest; 2005; 23(7):635-42. PubMed ID: 16305991
[TBL] [Abstract][Full Text] [Related]
33. Dual targeting of epigenetic therapy in cancer.
Hellebrekers DM; Griffioen AW; van Engeland M
Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.
Arts J; de Schepper S; Van Emelen K
Curr Med Chem; 2003 Nov; 10(22):2343-50. PubMed ID: 14529477
[TBL] [Abstract][Full Text] [Related]
35. Chromatin modifying agents - the cutting edge of anticancer therapy.
Kwa FA; Balcerczyk A; Licciardi P; El-Osta A; Karagiannis TC
Drug Discov Today; 2011 Jul; 16(13-14):543-7. PubMed ID: 21664485
[TBL] [Abstract][Full Text] [Related]
36. Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.
Claes B; Buysschaert I; Lambrechts D
Heredity (Edinb); 2010 Jul; 105(1):152-60. PubMed ID: 20389307
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Ma X; Ezzeldin HH; Diasio RB
Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
[TBL] [Abstract][Full Text] [Related]
38. Chromatin-modifying agents in anti-cancer therapy.
Seidel C; Florean C; Schnekenburger M; Dicato M; Diederich M
Biochimie; 2012 Nov; 94(11):2264-79. PubMed ID: 22627380
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.
Bruserud Ø; Stapnes C; Ersvaer E; Gjertsen BT; Ryningen A
Curr Pharm Biotechnol; 2007 Dec; 8(6):388-400. PubMed ID: 18289048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
